Therapeutic Advances in Neurological Disorders
@TANeurolDisord
A leading gold #OpenAccess journal in clinical neurology | IF 5.9 CiteScore 9.0 | π§ Follow us for neurological research and news.
ID:1088444597775228931
http://journals.sagepub.com/home/tana 24-01-2019 14:33:09
687 Tweets
630 Followers
602 Following
Follow People
Dr. Brandon Beaber
Neurologist and MS specialist. YouTube creator. Author of 'Resilience in the Face of Multiple Sclerosis'. Father of 2. Tweets my own & not medical advice.
Lyell Jones MD
Professor of Neurology @MayoClinic. Editor-in-chief @ContinuumAAN. Proud @AANMember. Improving systems of care and healthcare value for our patients
Gavin Giovannoni, aka Prof G
I published βCan artificial intelligence algorithms fall in love?β on @Medium https://t.co/0r8JsLayv2
Kailash Bhatia
Editor Movement Disorders Clinical Practise; Professor of Clinical Neurology, Queen Square, UCL; Chairman MSA Trust UK; Opinions my own
Xavier Montalban
Professor of Neurology, Chair Department of Neurology, Campus Hospitalari Vall d'Hebron @vallhebron (Barcelona), Director @Cemcat_em . Opinions are my own
It's time for another pick for #ThrowbackThursday :
This German guideline for the management of myasthenic syndromes is one of our most viewed articles from the past year. We hope you find it helpful!
journals.sagepub.com/doi/10.1177/17β¦π
π§ Serum neurofilament light levels may predict #MultipleSclerosis conversion. Explore insights from the REFLEX study's post hoc analysis on baseline sNfL correlations and treatment outcomes. Jens Kuhle Mark S Freedman
Read more: journals.sagepub.com/doi/full/10.11β¦
π Discover insights into treatment switches in #MultipleSclerosis from the German MS Registry. Explore predictors, reasons, and long-term outcomes in this retrospective analysis.
Read more: journals.sagepub.com/doi/full/10.11β¦
π§ Explore sex differences in MS relapse outcomes in this latest study led by researchers from UniversitΓ€t Bern. Discover insights from our analysis of 134 relapse events, revealing factors shaping recovery and prognosis.
Read more: journals.sagepub.com/doi/full/10.11β¦
π‘ A unique case report detailing patisiran exposure during early pregnancy in a woman with hereditary transthyretin-related amyloidosis. Learn about the careful considerations and monitoring involved in managing this rare scenario.
Read more: journals.sagepub.com/doi/full/10.11β¦
UniversitΓ© de Lausanne
π Explore real-world evidence from Germany on shifting treatment paradigms in #MultipleSclerosis care. Tjalf Ziemssen and team unveil insights into the adoption of early highly effective treatment.
Read more: journals.sagepub.com/doi/full/10.11β¦
#MSresearch #Neurology
π Exploring the treatment landscape for NMOSD patients in China: insights from a comprehensive cross-sectional survey. From diagnostic challenges to treatment satisfaction, learn about the journey here:
journals.sagepub.com/doi/full/10.11β¦
#RareDiseases #HealthcareAccess
𧬠Dive into the latest research comparing #ofatumumab with oral therapies for relapsing multiple sclerosis patients. Propensity score analyses unveil compelling insights.
Read more: journals.sagepub.com/doi/full/10.11β¦
#MultipleSclerosis #MedicalResearch
Unveiling a complex neurological presentation: Explore the intriguing case of concurrent acute sensorimotor axonal neuropathy and disseminated encephalitis associated with Chlamydia pneumoniae infection.
Read more: journals.sagepub.com/doi/full/10.11β¦
#Neuroscience #CaseStudy ππ¬
Comparative study reveals disparities in disease-modifying therapy initiation for multiple sclerosis patients across three major registries.
Explore the findings and implications: journals.sagepub.com/doi/full/10.11β¦
#MultipleSclerosis #HealthcareResearch π§ π
πInsights from a 16-week study on #Pimavanserin 's effect on activities of daily living in Parkinson's disease psychosis. Check out the findings and implications here: journals.sagepub.com/doi/full/10.11β¦
#Research #Neurology #Healthcare π
In our final Editor's pick from 2023 (10/10), Suraj Muley and Said Beydoun discuss the impact of the recent updated chronic inflammatory demyelinating polyneuropathy guideline on everyday clinical practice:
journals.sagepub.com/doi/full/10.11β¦π #ThrowbackThursday
A diabetes drug from the family of blockbuster weight-loss drugs slowed development of #Parkinsons disease symptoms by a small but statistically significant amount:
nature.com/articles/d4158β¦
In our #ThrobackThurday 2023 Editor's picks series, part 9/10:
Task Force AHSCT of the German Multiple Sclerosis Competence Network present an expert consensus recommendations on autologous hematopoietic #StemCell transplantation in #MultipleSclerosis :
journals.sagepub.com/doi/full/10.11β¦π
New online!
Can serum neurofilament light (sNfL) chain level predict #MultipleSclerosis conversion, and can the conversion risk be mitigated by subcutaneous IFN Ξ²-1a?
journals.sagepub.com/doi/full/10.11β¦ π
This #ThrowbackThursday , we feature again 2023 Editor's picks, this time part 8/10:
Here, Laura Schnetzer and colleagues describe neuroanatomical features of vascular locked-in and locked-in-plus syndrome:
journals.sagepub.com/doi/full/10.11β¦ π
New online!
What are the barriers to treatment in early #MultipleSclerosis in different healthcare systems?
Here, a multinational author team reports on disease-modifying therapy initiation patterns in three large MS populations from USA, UK and Germany:
journals.sagepub.com/doi/full/10.11β¦π